Lantus, Insulin Glargine

Bookmark

Add to MyYahoo RSS

Lantus, Insulin Glargine News

News on Lantus, Insulin Glargine (generic) continually updated from thousands of sources around the net.

Thursday Apr 10 | Business Wire

Research and Markets: Global Type 2 Diabetes Therapeutics Market 2013-2019

There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose.

Comment?

Related Topix: Medicine, Health, Diabetes

Tue Apr 01, 2014

PR-inside.com

New Report Available: Sanofi-Aventis K.K. - Pharmaceuticals &...

Sanofi-Aventis K.K. is a pharmaceutical company. The company develops, manufactures and commercializes generic drugs and medical equipment.

Comment?

Related Topix: Medicine, Diabetes, Health, Plaquenil, Hydroxychloroquine (generic), Sanofi Pasteur, World News, Japan,

Thu Mar 27, 2014

The Motley Fool

Here's How Sanofi Hopes to Survive Post-Lantus

Lantus makes up 17% of Sanofi's global sales and has posted two consecutive years of nearly 20% growth.

Comment?

Related Topix: Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin

Mon Mar 24, 2014

Sys-Con Media

Investigation Report on China Insulin Glargine Market, 2009-2018

Markets has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" report to their offering.

Comment?

Related Topix: Diabetes, Health, Insulin (generic), Humulin, Novolin

Thu Mar 20, 2014

Pharmaceutical Technology

Adocia's Combination Insulin Formulation Shows Positive Results in Phase I/II Trial

Adocia , a biotech company that specializes in the development of approved protein formulations, has reported positive results for the first clinical trial of its combination insulin formulation of fast- and long-acting insulin in patients with type I diabetes.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Humalog, Insulin Lispro (generic), Pharmacology

Hispanic Business

Zealand Pharma A/S announces Full Year results and publication of the Annual Report for 2013

Copenhagen, 2014-03-20 09:02 CET -- Company Announcement No. 4/2014 Zealand Pharma A/S announces Full Year results and publication of the Annual Report for 2013 -- Commercial launch of Lyxumia , the first peptide medicine from Zealand pipeline to reach the market, marks key transition to a sustainable revenue stream -- Important pipeline advances: ... (more)

Comment?

Related Topix: Medicine, Health, Diabetes, Insulin (generic), Humulin, Novolin

•••
•••
•••
•••
•••
•••
•••
•••